Gudrun Schleiermacher

Inserm — France

Medicine · Health Sciences

57h-index14.5kcitations328works2.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuroblastoma Research and Treatments(214), Cancer, Hypoxia, and Metabolism(76), Cancer therapeutics and mechanisms(46), Cancer Genomics and Diagnostics(43), Renal and related cancers(37)

Publications322 total

Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial
Journal of Clinical Oncology·2025· 1 citedOpen Access
Differential chromatin accessibility response to retinoic acid in neuroblastoma with ATRX in-frame-deletions versus ATRX loss-of-function
Neoplasia·2025Open Access
Establishing a national multidisciplinary board for complex pediatric renal tumors: Lessons learned
Bulletin du Cancer·2025
Figure S3 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
2025Open Access
Figure S5 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
2025Open Access
Supplementary Data DS1 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
2025Open Access
Figure S6 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
2025Open Access
Figure S4 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
2025Open Access
Figure S2 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
2025Open Access
Figure S1 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
2025Open Access
KDM5-driven transcriptional noise fuels plasticity-led awakening and relapse in paediatric cancer
2025Open Access
Chemo‐Immunotherapy Rescue for High‐Risk Neuroblastoma Patients With Progressive Disease Before High‐Dose Chemotherapy: Real‐World Data From the SACHA‐France Study
Pediatric Blood & Cancer·2025· 1 citedOpen Access
Outcome of Premature Infants Treated With Chemotherapy for Neuroblastoma in France
Pediatric Blood & Cancer·2025
Atypical Neuroblastoma With Absent Urinary Catecholamine Excretion and <sup>123</sup>ImIBG Avidity Are of Favorable Outcome: A Retrospective French Single‐Center Study
Pediatric Blood & Cancer·2025Open Access
1548P Feasibility and activity of chemo-immunotherapy in adolescents and young adults with relapsed/progressive high-risk neuroblastoma: Real-world data from SACHA-France
Annals of Oncology·2025
International neuroblastoma risk group consortium: a model of networking for rare cancers
JNCI Journal of the National Cancer Institute·2025· 2 citedOpen Access
Neuroblastoma in Infants: Long‐Term Survival From INES Protocols A SIOPEN Study
Pediatric Blood & Cancer·2025· 2 citedOpen Access
Differential chromatin response to retinoic acid in neuroblastoma according to type of <i>ATRX</i> mutation
2025Open Access
Outcome of premature infants treated with chemotherapy for neuroblastoma in France.
2025Open Access
Accelerating Drug Development for Neuroblastoma: Consensus Statement From the Third Neuroblastoma Drug Development Strategy Forum
Pediatric Blood & Cancer·2025· 3 citedOpen Access
page 1 of 17Next →

Frequent Co-authors

Olivier Delattre(25), Isabelle Janoueix‐Lerosey(20), Dominique Valteau‐Couanet(18), Jean Michon(17), Valérie Combaret(14), Gaëlle Pierron(12), Eve Lapouble(11), Frank Speleman(10), Peter F. Ambros(9), Andrew D.J. Pearson(9), John M. Maris(8), Akira Nakagawara(8), Rosa Noguera(8), Wendy B. London(7), Julie R. Park(7), Susan L. Cohn(7), Virginie Bernard(7), Angela Bellini(7), Ruth Ladenstein(7), Katleen De Preter(7)